Explore Dr. Retzler’s HormoneSynergy® Longevity Medicine Resource Library
Longevity Medicine
Cart

Longevity Medicine, Functional Wellness & Anti-Aging Insights from HormoneSynergy®

Welcome to the HormoneSynergy® Longevity Medicine Blog, a physician-guided clinical library led by Dr. Kathryn Retzler. Our articles cover the systems that most often shape health with age: metabolic health, hormones, cardiovascular and kidney risk, body composition, bone and muscle, brain health, sleep, gut health, nutrition, supplements, and the biology of aging.

The library is organized around clinical questions rather than trends. Some articles review new research. Others explain testing, treatment, nutrition, or a condition patients commonly encounter. Across the collection, the standard is the same: evidence first, appropriate uncertainty, and enough clinical context to separate useful medicine from wellness marketing.

Start with the HormoneSynergy® Longevity Medicine Framework

New & recently updated:

Metabolic Health & Insulin Resistance

Clinical resources on insulin resistance, glucose regulation, metabolic syndrome, visceral fat, prediabetes, obesity and GLP-1-based care within a broader longevity medicine plan.

Kidney Health & Cardiovascular-Kidney-Metabolic Health

Kidney health belongs in the same clinical conversation as blood pressure, diabetes, insulin resistance, obesity and cardiovascular risk. These resources cover early detection, CKD, albuminuria, nutrition and CKM health.

Body Composition, Bone & Muscle Longevity

Resources on DEXA, SECA, visceral fat, lean mass, sarcopenia, bone density, exercise and preservation of physical reserve with age.

Gut Health, Microbiome & Immune Signaling

Clinical education on the microbiome, intestinal barrier, fiber, inflammation, gut-brain signaling, immune biology and the growing connections between gut, metabolic and kidney health.

Food Quality, Vitamins, Supplements & Wellness Claims

Evidence-based guidance on nutrient gaps, supplement quality, interactions, food claims and longevity products, with an emphasis on where supplementation helps and where marketing outruns the evidence.

  • Insulin Resistance and Brain Health: A Longevity Medicine Perspective

    by Daniel Soule
    Insulin resistance and brain health illustration showing metabolic signaling and cognitive function from a longevity medicine perspective

    Insulin resistance is a foundational driver of metabolic dysfunction that may also influence brain health over time. Understanding this connection is key to protecting long-term cognitive function and overall longevity.

  • Fasting Insulin and Brain Health: An Early Signal in Cognitive Longevity

    by Daniel Soule
    Fasting Insulin and Brain Health: An Early Signal in Cognitive Longevity

    Fasting insulin is one of the earliest indicators of metabolic dysfunction—and it may also play a role in long-term brain health. Even when glucose appears normal, elevated insulin can signal underlying risk.

  • Lipoprotein(a) [Lp(a)]: The Genetic Risk Marker Most People Miss

    by Daniel Soule
    Lipoprotein(a) genetic cardiovascular risk marker clinical dashboard longevity medicine

    Lp(a) is a genetic cardiovascular risk marker often missed in routine labs. Learn why elevated lipoprotein(a) matters for longevity and preventive cardiology.

  • Is Alzheimer’s Really “Type 3 Diabetes”? What That Idea Gets Right—and What It Misses

    by Daniel Soule
    brain insulin resistance cognitive decline metabolic health connection longevity medicine

    The idea that Alzheimer’s is “Type 3 diabetes” has gained traction—but it’s not the full story. Here’s what’s true, what’s oversimplified, and how this fits into a longevity medicine perspective.

  • Statins and Alzheimer’s: What the Data Actually Shows (and What It Doesn’t)

    by Daniel Soule
    brain and cardiovascular health connection statins and Alzheimer’s risk clinical perspective longevity medicine

    A recent large observational study suggests statins may be associated with lower Alzheimer’s risk, but the full story is more complex. Here’s what the data actually shows, what it does not prove, and how it fits into a longevity medicine perspective.

  • ApoB Optimal Ranges: What Levels Mean for Cardiovascular Risk

    by Daniel Soule
    ApoB optimal ranges cardiovascular risk clinical dashboard particle levels longevity medicine

    ApoB reflects the number of atherogenic particles in circulation. Understanding optimal ranges helps clarify cardiovascular risk beyond traditional cholesterol measurements.

  • Lp(a) Thresholds: What Is High and What It Means for Cardiovascular Risk

    by Daniel Soule
    lpa-thresholds-cardiovascular-risk-levels-hormonesynergy.jpg

    Lp(a) levels are genetically determined, but knowing what is considered high can help clarify cardiovascular risk. Understanding Lp(a) thresholds is key to interpreting this often-overlooked marker.

  • ApoB vs LDL-P: Which Better Reflects Cardiovascular Risk?

    by Daniel Soule
    ApoB vs LDL-P cardiovascular particle risk comparison clinical dashboard longevity medicine

    ApoB and LDL-P both estimate atherogenic particle burden, but they are not identical. Understanding how they differ helps clarify cardiovascular risk beyond standard cholesterol panels.

  • LDL-C vs LDL-P (Discordance): Why Cholesterol Numbers Can Miss Risk

    by Daniel Soule
    LDL-C vs LDL-P discordance clinical dashboard for cardiovascular risk and longevity medicine

    LDL-C and LDL-P are related, but they are not the same. In some people, LDL cholesterol appears normal while LDL particle number remains elevated, creating a discordance that can underestimate cardiovascular risk.

  • Longevity Medicine vs. Anti-Aging: What We Mean, What We Don’t, and Why It Matters

    by Daniel Soule
    Longevity Medicine vs Anti-Aging educational banner from HormoneSynergy® showing the difference between marketing-driven anti-aging claims and a more honest preventive longevity medicine approach

    “Anti-aging” may sound appealing, but it is often more marketing than medicine. At HormoneSynergy®, we believe in a more honest approach: longevity medicine focused on preventing, slowing, and sometimes helping reverse the common diseases and patterns associated with aging through earlier, more thoughtful care.

  • LDL Particle Number (LDL-P) and Cardiovascular Risk

    by Daniel Soule
    LDL particle number (LDL-P) clinical dashboard showing particle count and cardiovascular risk assessment in longevity medicine

    LDL particle number (LDL-P) provides a deeper look at cardiovascular risk by measuring the number of LDL particles, not just the cholesterol they carry. It can reveal hidden risk even when LDL-C appears normal.

  • Remnant Cholesterol: What It Adds to Cardiovascular Risk Assessment

    by Daniel Soule
    Remnant Cholesterol: What It Adds to Cardiovascular Risk Assessment

    Remnant cholesterol reflects the cholesterol carried in triglyceride-rich lipoprotein remnants. It often rises alongside insulin resistance, elevated triglycerides, visceral fat and other features of metabolic dysfunction, and it can help explain cardiovascular risk that is not obvious from LDL-C alone. Like ApoB, it adds information rather than replacing the rest of the lipid panel.